Lars Bullinger, MD, from the University Hospital of Ulm, Ulm, Germany talks to us about the new technological advancements in research, namely next-generation sequencing, which has revolutionised the field of molecular diagnostics. He mentions that there is a growing need to study molecular markers of diseases such as acute myeloid leukemia (AML), and it would be ideal to integrate these new technologies into the clinical routine of physicians. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.